RxDoctor Payments Data

Humera Malik, MD

Internal Medicine · Saginaw, MINPI 1861704660

Payments from drug & device makers

$713in general payments, 2019–2025

Across 54 payments — averaging $13.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$277
  • Johnson & Johnson$83
  • GSK$63
  • Amarin Pharma, Inc.$57
  • Lilly USA, LLC$53
  • Astellas Pharma US Inc$36
  • plus $145 from 6 others

What the payments were for

  • Food & beverage$69898%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$713 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$54,199
Medicare patients
154
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$121,180
JardianceEmpagliflozin90$100,182
EliquisApixaban75$87,552
MounjaroTirzepatide42$49,367
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$34,940
TrulicityDulaglutide24$34,038
Tresiba Flextouch U-100Insulin Degludec17$21,134
XareltoRivaroxaban12$17,548
LinzessLinaclotide20$16,035
MyrbetriqMirabegron12$14,040
Breo ElliptaFluticasone/Vilanterol21$10,845
PaxlovidNirmatrelvir/Ritonavir15$8,097
Novolog FlexpenInsulin Aspart34$7,826
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,542
Atorvastatin Calcium393$6,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$277$121,18064 claims
PfizerEliquis, Paxlovid$30$95,64990 claims
Lilly USA, LLCMounjaro, Trulicity$53$83,40466 claims
GSKTrelegy Ellipta, Breo Ellipta$63$45,78659 claims
Johnson & JohnsonXarelto$83$17,54812 claims
Astellas Pharma US IncMyrbetriq$36$14,04012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →